Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Short Interest Down 89.2% in July

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) was the target of a large decrease in short interest during the month of July. As of July 31st, there was short interest totalling 63,900 shares, a decrease of 89.2% from the July 15th total of 589,700 shares. Based on an average daily volume of 3,630,000 shares, the short-interest ratio is presently 0.0 days.

Biodexa Pharmaceuticals Stock Down 1.7 %

NASDAQ:BDRX traded down $0.01 during mid-day trading on Wednesday, hitting $0.59. 18,949 shares of the company’s stock were exchanged, compared to its average volume of 2,862,241. Biodexa Pharmaceuticals has a fifty-two week low of $0.55 and a fifty-two week high of $9.64. The company has a quick ratio of 1.26, a current ratio of 1.26 and a debt-to-equity ratio of 0.06. The company has a 50 day simple moving average of $0.85 and a 200-day simple moving average of $1.09.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme.